Holliston, MA — Digilab, Inc. is pleased to announce the appointment of Santo J. Costa to its Board of Directors. Mr. Costa is currently Of Counsel with Smith, Anderson, Blount, Dorsett, Mitchell & Jerrigan, L.L.P. of Raleigh, North Carolina, where he specializes in corporate law for life science companies.

Mr. Costa is the former Vice Chairman, President and COO of Quintiles Transnational Corp. As President and Chief Operating Officer, he was responsible for all operating divisions and worldwide business development. During this time, the company’s revenues rose from approximately $90 million to $1.6 billion, with growth being fueled by a combination of internal growth and acquisitions as Mr. Costa oversaw the successful integration of over 40 companies, at a time when Quintiles was transformed from a contract research organization to a fully integrated world wide service company, and the market leader in providing a full range of product development, commercialization and information solutions, and health care policy consulting to the pharmaceutical and device industries and governmental agencies.

“We look forward to the significant contributions we know that Sandy will make, and are pleased to have him join our Board,” said Sid Braginsky, Chairman and CEO of Digilab, Inc. “Sandy brings a breadth of experience to the Board, including substantial growth, organically and through acquisitions and a proven track record with successful life sciences and high technology ventures.”

Prior to joining Quintiles, Mr. Costa was Senior Vice President, Administration and General Counsel of Glaxo Inc., where he sat on the Board of Directors and was deeply involved in managing Glaxo’s growth from $600 million to nearly $3 billion in annual revenues in 1993. Prior to Glaxo, Mr. Costa was U.S. Area Counsel for Merrill Dow Pharmaceuticals. He started his career as Food and Drug Counsel with Norwich Eaton Pharmaceuticals.

In addition, Mr. Costa has served as a Director for a number of health sciences companies. He currently sits on the board of OSI Pharmaceuticals and is Chairman of Labopharm, Inc. He is an Adjunct Professor in the clinical research program at the Campbell University School of Pharmacy. Mr. Costa received his BS in pharmacy and his Juris Doctor degrees from St. John’s University and is licensed to practice pharmacy in New York and Rhode Island and licensed to practice law in New York, Ohio and North Carolina.

About Digilab, Inc.

Digilab has been a global leader in molecular spectroscopy systems for over 40 years focusing on sample preparation, bioinformatics, and detection/analysis tools for the chemical, life sciences research and in-vitro diagnostics markets.

In June of 2006, Digilab acquired SpectraCode Inc. in West Lafayette, Indiana. This acquisition provides Digilab core competence and products in high growth applications which require the versatility and ease of use of Raman Molecular Spectroscopy.

In November of 2007, Digilab acquired Genomic Solutions (which included Gene Machines, Cartesian, and BioRobotics) and MAIA Scientific. These acquisitions broaden Digilab’s global footprint in both the Life Sciences Research pre-analytics market and its commitment to provide downstream systems and solutions which will have broad application in clinical diagnostics.

Digilab, via a series of acquisitions and partnerships, is implementing this business model. Its vision and strategy is retention/expansion of market awareness as a company with unique and high value products for principally the health sciences markets.